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Background: Pregnant women are the highest priority group for annual influenza vaccination. Studies have shown
unacceptably low uptake of both seasonal and pandemic A/H1N1 influenza vaccination among pregnant women.
This paper will describe the study protocol and methodology of a randomised controlled trial designed to assess
the effectiveness of a brief educational intervention in improving the uptake of seasonal influenza vaccine among
pregnant women in Hong Kong.
Methods: A randomised controlled trial will be conducted with pregnant women in at least the second trimester
of pregnancy from four publicly funded hospital antenatal clinics in Hong Kong. Participants will be randomly
assigned to either one of the two treatment groups: standard care (control) or standard care plus brief education
(intervention). Pregnant women in the standard care group will receive the usual antenatal care with an
educational pamphlet developed by the Hong Kong Centre for Health Protection and those in the intervention
group will be provided with usual care plus a brief ten-minute education intervention. Content of the education
session will cover four core components recommended in the research literature. The primary study outcome will
be the proportion of participants who have received influenza vaccine during their pregnancy. A total of 184
pregnant women (92 per group) will be required to give an 80% power to detect a treatment effect of 15%.
Discussion: Most intervention studies aimed at improving influenza vaccination rates in pregnant women have
targeted obstetric-care providers and the results of the two patient-oriented RCT interventions are conflicting. The
high priority for vaccination given to pregnant women and the low influenza vaccination rate among pregnant
women worldwide strongly indicates a need for interventions to improve uptake.
Trial registration: This trial is registered with the Clinical Trials Registry at www.clinicaltrials.gov (NCT01772901).
Keywords: Influenza, Influenza vaccination, Antenatal, Prenatal, Pregnant women, Pregnancy, Education,
Interventions, Randomised controlled trialBackground
Influenza is a threat to human life, global economies, and
security in our increasingly interconnected world [1]. Due
to its high attack rate and continuous antigenic drift, sea-
sonal influenza causes 3 to 5 million cases of severe illness
and 250,000 to 500,000 deaths every year [2]. In particular,
the Influenza A virus has caused a number of severe pan-
demics over the past century. The Spanish flu pandemic
in 1918 killed approximately 50 to 100 million people* Correspondence: tarrantm@hku.hk
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stated.while the Asian and Hong Kong flus in 1957 and 1968
caused 4 to 8 million deaths in total [3,4]. In the recent
2009 A/H1N1 influenza pandemic it is estimated that
more than 150,000 people died, and in contrast to typical
influenza season, 80% were younger than 65 years of age
[5]. In addition to significant influenza-related morbidity
and mortality, there is a substantial socioeconomic cost at-
tributable to influenza. Every year, influenza results in dir-
ect societal costs from absenteeism, lost productivity,
related medical treatments, and excess hospitalization and
indirect costs from preventive and control measurestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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programmes, school closure, and quarantine [6,7].
According to both the World Health Organization
(WHO) and the Centers for Disease Control and Preven-
tion (CDC), pregnant women, young children, especially
those under two years of age, people with chronic illnesses,
those aged 65 and above, and healthcare workers are all
more susceptible to influenza infection [2,8]. Pregnant
women have higher rates of influenza-related morbidity
and mortality because of the immunologic and physiologic
alterations that occur in pregnancy, and which affect the re-
spiratory, cardiovascular, and other organ major systems
[9,10]. During the 2009 A/H1N1 influenza pandemic [11],
pregnant women contracting influenza were more likely to
experience pregnancy complications such as emergency
caesarean section, stillbirth, neonatal death, preterm birth
[12-14], low birth weight [11,14,15], hospitalization [11,14,16],
and maternal death [10,15,16]. Although the risk of influ-
enza infection is lower in non-pandemic years, infected
pregnant women still have a greater risk of influenza mor-
tality, pregnancy complications and hospital admission
[17-19]. They also have a higher risk of being hospitalized
for longer duration [18]. The risk of hospitalization in preg-
nant women with influenza is equal to, or higher than, the
rate in older adults aged 65 to 69 years and people with
underlying chronic illnesses [20,21].
Benefits of influenza vaccine
Influenza vaccine has been demonstrated to be both bene-
ficial and safe for pregnant women and their foetus at all
stages of pregnancy [22-24]. Influenza vaccine reduces both
maternal complications from influenza and infant morbid-
ity in the first six months of life. The recommendation to
vaccinate pregnant women with influenza vaccine was ori-
ginally proposed in 1960, ten years after the influenza vac-
cine was first developed [25]. Although the evidence on the
safety and benefits of influenza vaccination during preg-
nancy was limited at the time, the US Surgeon General first
recommended women to receive influenza vaccine during
pregnancy to prevent flu-related complications and deaths
[26]. Given the increasing evidence demonstrating the safety
and immunogenicity of influenza vaccination in pregnancy
and the maternal antibody transfer to the unborn in-
fant, in 2005 the CDC recommended that all pregnant
women receive trivalent inactivated influenza vaccine
(TIV) [27]. In 2010, in the first randomised controlled
trial, researchers administered influenza vaccine to preg-
nant women in Bangladesh who were in their third tri-
mester [28]. The vaccine reduced the incidence of febrile
respiratory illness in pregnant women by 36% and reduced
the incidence of laboratory confirmed influenza in infants
up to six months of age by 63%. Further observational
studies have shown similar reductions in both maternal
and infant morbidity and mortality [29,30].In addition, studies have shown that influenza vac-
cine during pregnancy, even in the first trimester,
poses no additional risk to the developing foetus. In
a recent study of over 50,000 pregnant women in
Denmark, of whom over 7,000 had received the 2009
A/H1N1 influenza vaccine, there was no excess risk of
miscarriage or stillbirth among vaccinated women [31].
A smaller study of 323 vaccinated pregnant women
and 1,329 matched control subjects also found no ex-
cess risk of spontaneous abortion or foetal malformations
among participants receiving the 2009 A/H1N1 vaccine,
irrespective of time of vaccination [32]. To date, no study
has shown any increased risk of vaccine-related maternal
complications or adverse foetal outcomes [24,33-35].
Given that a single vaccine can protect the pregnant
women, the foetus and the infant, a 3-for-1 benefit, in
2012 the WHO [36], recommended that among high risk
groups, pregnant women have the highest priority in sea-
sonal influenza vaccination programmes. This recommen-
dation was subsequently adopted by a number of other
national governments [23,37-39].Influenza vaccine uptake rates
Despite the recommendations from the WHO and na-
tional governments, the uptake of influenza vaccine
among pregnant women in most developed countries is
still lower than uptake in general population, with rates
ranging from 1.7% to 76.4% [40-49]. Limited studies have
been conducted in Asia, mostly in Hong Kong. A pre-
pandemic study by Lau et al. found that only 3.9% of preg-
nant women had been immunized with seasonal influenza
vaccine [50]. Coverage during the 2009–10 A/H1N1 pan-
demic was 4.9% [51], while a recent population-based
post-pandemic study during the 2010–11 influenza season
found an uptake rate of 1.7% [48].
A number of studies have found that many pregnant
women are still unaware that they should be vaccinated
or have substantial concerns about adverse effects of
the vaccine on them and/or their foetus [51-53]. In
addition, many health-care providers (HCPs) do not
routinely recommend that pregnant women be vacci-
nated as they themselves are often unaware of the rec-
ommendations or also share concerns about adverse
effects of vaccination [54-58]. Furthermore, HCPs often
hesitate to recommend vaccination to their pregnant
clients, not because they believe the vaccine is actually
unsafe during pregnancy [58], but likely because they
perceive clients may blame the vaccine, and by exten-
sion them, for any negative pregnancy outcomes. Re-
search has shown that pregnant women with more
knowledge about the potential complications of influ-
enza and of the safety of the influenza vaccine are more
likely to be vaccinated [51,58,59].
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To date however, few interventions have attempted to in-
crease influenza vaccine uptake among pregnant women.
Of the few interventions that have been conducted, most
of the studies either have targeted healthcare professionals
to encourage them to discuss influenza vaccine with preg-
nant women and to encourage pregnant women to take
the vaccine or have involved multicomponent interven-
tions as such the individual effect of patient-focused inter-
vention cannot be evaluated [60-68]. Only three studies
have investigated patient-targeted interventions, of which
one used a historical control group and two were rando-
mised controlled trials (RCTs). Yudin et al. found that an
education intervention increased knowledge of influenza
and vaccine rates from 19% (historical control) to 56%
(post intervention) [68]. Furthermore, Meharry et al. eval-
uated the impact of providing an educational pamphlet
with or without a statement verbalizing the benefit of in-
fluenza vaccine to both pregnant women and their infants
from birth to six months of age and found that these mea-
sures increased vaccination rates from 46.9% (control) to
79% (educational pamphlet only) and 86.1% (educational
pamphlet with verbalized benefit statement) [62]. However,
Moniz et al. found that providing 12 weekly text messages
about the importance of influenza vaccination in pregnancy
did not significantly increase vaccination uptake [63]. Given
the conflicting results from the few published studies,
which were all conducted in North America, it is not clear
if patient-oriented interventions can be effective in promot-
ing influenza vaccination uptake among pregnant women,
particularly in an Asian or Chinese population.
The low rate of vaccine uptake among this target group
and the paucity of evaluated interventions both indicate
a clear need to develop and test interventions to increase
the low rate of influenza vaccine uptake among pregnant
women. In addition, publicly-funded antenatal clinics in
Hong Kong provide the majority of care to pregnant
women but do not provide influenza vaccination. There-
fore, pregnant women must obtain the vaccine from private
settings, which are widely dispersed throughout the city.
Thus, interventions targeting HCPs may not be effective in
this and similar settings. Interventions targeting pregnant
women themselves are more likely to be effective in in-
creasing influenza vaccine uptake. If demonstrated to be
effective, the proposed intervention could easily be adopted
in various antenatal settings. Increasing the uptake of influ-
enza vaccine among pregnant women could prevent un-
necessary hospitalizations among pregnant women and
newborn infants, both of whom are at greater risk of excess
morbidity and mortality from influenza infection.
Aims and hypotheses
The aim of this randomised controlled trial is to deter-
mine whether a brief educational intervention willincrease uptake of influenza vaccine among pregnant
women when compared with standard antenatal care.
The primary study hypothesis is that the influenza vac-
cination rate will be increased among participants who
receive the brief educational intervention when com-
pared with those who receive standard antenatal care.
The secondary study hypotheses are that participants in
the intervention group will have a higher rate of self-
initiated discussion about influenza vaccination with their
healthcare provider, a higher rate of requesting to receive
the influenza vaccine, and improved knowledge of and
more positive attitudes toward influenza and influenza
vaccine, when compared with those who receive standard
antenatal care.
Methods
This study will be an open-label, randomised controlled
trial. Pregnant women in at least the second trimester of
pregnancy will be recruited from the antenatal clinics of
four public hospitals geographically dispersed throughout
Hong Kong. Ethical approval has been obtained from the
Institutional Review Boards of all the participating study
sites and informed written consent will be obtained from
participants who have agreed to participate but prior to
randomisation. The design, implementation and reporting
of this study will conform to the guidelines listed in the
ICH-GCP, Declaration of Helsinki, standard CONSORT
2010 Statement [69].
Study participants
Pregnant women attending the antenatal clinics of the
four public hospitals will be screened for eligibility. Eli-
gible patients are pregnant women: (a) with a singleton
pregnancy; (b) at least 18 years of age; (c) in at least the
second trimester of pregnancy; (d) Cantonese speaking;
(e) Hong Kong resident; (f ) without serious medical or
obstetrical complications; (g) have not received the influ-
enza vaccine in this pregnancy; and (h) who will be stay-
ing in Hong Kong for at least two weeks after birth.
Randomisation
A research nurse will attend the antenatal clinics at the re-
spective study sites and screen pregnant women for eligi-
bility. Eligible women will be approached and informed
about the study. Those who agree to participate will be
given more in-depth information about the study details
and informed written consent will be obtained. A third
party, who will not be involved in any part of the study, will
develop a computer-generated randomised treatment allo-
cation sequence for each study site using random block
sizes of two to eight. The treatment assignments will each
be placed in sequentially numbered, opaque, sealed enve-
lopes. After obtaining informed written consent, the re-
search nurse will select the next envelope in the sequence
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who will not be involved in participant recruitment and
will be blinded to the participants’ treatment allocation,
will be responsible for the assessment of the study
outcomes.
Study interventions
This trial compares standard antenatal care to a brief one-
to-one, 10-minute education session by a research nurse
explaining the facts of influenza and influenza vaccine and
answering participant questions. Briefly, usual antenatal
care consists of routine checking of the maternal and foetal
health by either clinic midwives or obstetricians along
with health education to promote a healthy pregnancy.
Special childbirth preparation and breastfeeding classes are
available to the pregnant women for no additional cost.
Routine antenatal care does not usually encompass specific
education or recommendations about influenza vaccin-
ation. However, we will provide the standard care group
participants with an educational pamphlet on influenza
vaccine in pregnancy developed by the Hong Kong Centre
for Health Protection (CHP), which is freely available in all
antenatal clinics.
The brief education group will receive the usual care
plus one-to-one, brief education that will focus on four
key recommendations identified from the research lit-
erature [52,60,70-73]: (i) inform pregnant women of
vaccination recommendations, (ii) encourage discussion
with their HCPs, (iii) increase accessibility of vaccine
(make referral to clinics where vaccine can be obtained),
and (iv) provide credible information from the govern-
ment official website and provide the website URL. Spe-
cifically, for participants in the education group in this
study we will inform them about the: (i) WHO and
Hong Kong CHP recommendations regarding influenza
vaccine during pregnancy, (ii) potential complications
associated with influenza infection during pregnancy
and for young infants, (iii) safety of influenza vaccine
for pregnant women and the foetus, and (iv) potential
benefits of influenza vaccine for the pregnant women,
the foetus and the infant, and (iv) where and how to get
the influenza vaccine in Hong Kong.
To ensure the consistency of intervention, one re-
search nurse will implement the intervention across the
four sites. The research nurse has completed extensive
education on the international and national vaccination
guidelines and the benefits and safety of influenza vac-
cination for pregnant women, as well as the implementa-
tion of randomised controlled trials.
Outcome measures
The primary study outcome is the influenza vaccination
rate during pregnancy in the control and intervention
groups. The secondary study outcomes are the proportionof participants initiating discussion about influenza vac-
cine with their health care provider, the proportion of
participants seeking out influenza vaccine, and the influ-
enza and influenza vaccine knowledge of participants in
the control and intervention groups after receiving the
intervention.
Data collection and measurements
After recruitment, pregnant women who agree to partici-
pate in the study and have signed a written consent form
will be asked to complete a standard baseline question-
naire that will include (i) key demographic data (i.e., age,
marital status, education level, family income, and employ-
ment status); (ii) maternal health data (i.e., pre-existing
health conditions, pregnancy related health problems, gra-
vidity and parity, and expected date of confinement), and
(iii) influenza and influenza vaccine knowledge. Partici-
pants will be followed up by telephone at two to three
weeks after their expected confinement date by a study re-
search assistant who will be blinded to their treatment
group allocation. During the follow-up telephone inter-
views, information will be collected on (i) influenza vac-
cination data (i.e., vaccination status, reasons for receiving
or not receiving the vaccine, discussion with HCPs, at-
tempts to receive vaccine, anti-vaccination advice from
HCP or family members, and vaccination status of family
members); (ii) health status during pregnancy (i.e., per-
ceived health status during pregnancy, pregnancy-induced
medical conditions, and respiratory illnesses and symp-
toms); (iii) actual birth data (i.e., date of birth, gender, ges-
tational age and birth weight); and (iv) postnatal influenza
and influenza vaccine knowledge.
Sample size
Previous Hong Kong studies show that the range of sea-
sonal influenza vaccine uptake among pregnant women
ranges from 1.7 to 5.0% [48,50,51]. From the literature,
studies have shown that with provider-focused interven-
tions, influenza vaccine uptake rates increased from 1 to
2% before the intervention to approximately 37% after
the intervention [64-66,68]. In addition, the Meharry
et al. study evaluating the educational pamphlet plus the
verbal statement increased vaccine uptake from 46.9% in
the control group to 86.1% in the intervention group
[62]. Thus, an estimate of the ‘normal’ prevalence of in-
fluenza vaccine uptake among pregnant women in Hong
Kong would be 5.0% and an increase to 20% would be
highly conservative but still clinically meaningful. Thus,
using a study power of .80 and a significance level of .05,
then 76 participants would be required for each group
calculated using the Gpower z-test [74]. After account-
ing for a loss to follow-up or dropout rate of around
20%, approximately 92 participants per group are re-
quired for a total of 184 participants. Recruitment would
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early October, and continue until all participants are
recruited.
Statistical analysis
The primary analyses will compare the proportion of par-
ticipants in the two study groups who have actually re-
ceived the influenza vaccine during their pregnancy. We
will assess the equivalency of treatment group allocation
by comparing the major socio-demographic indicators
(age, education, income). Between-group comparisons will
be made using a chi-squared test. The intention-to-treat
principle will be used with missing values taken as no vac-
cination. Each estimate will be accompanied by a 95%
confidence interval and a 5% level of significance will be
used in all statistical tests. Other data analysis will include
comparing the proportion of participants initiating discus-
sion of influenza vaccine with their health-care provider
and the proportion of participants seeking out influenza
vaccination, again using chi-square tests. The knowledge
level of the participants will be compared before and after
the intervention using chi-squared test and student’s
t-test. Data analysis will be performed using the Stata
version 13.1 statistical software [75].
Discussion
The current body of evidence does not provide sufficient
guidance on the effectiveness of patient-oriented interven-
tions in promoting influenza vaccination uptake among
pregnant women. The comprehensive intervention proto-
cols with structured content targeting individual pregnant
women increase the consistency of intervention delivery
and adherence to study protocols. The multiple outcomes
will provide valuable data to measure the impact of inter-
ventions. If brief education is shown to be effective in
improving influenza vaccine uptake, it can be a low cost
strategy to improve the low vaccination uptake among
pregnant women, which can be easily adopted in various
antenatal settings. Further studies can also be carried out
to investigate the feasibility of shortening the brief educa-
tion and also partnering it with providing on-site vaccin-
ation to maximize the potential benefit. Brief education can
also be a cost-effective intervention, as increased influenza
vaccination uptake would prevent unnecessary influenza-
related hospitalization, excess morbidity and mortality among
pregnant women and young infants.
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